Silo Pharma, Inc. - Common Stock (SILO)
0.4478
-0.0422 (-8.61%)
NASDAQ · Last Trade: May 21st, 3:45 PM EDT
Detailed Quote
| Previous Close | 0.4900 |
|---|---|
| Open | 0.4800 |
| Bid | 0.4455 |
| Ask | 0.4550 |
| Day's Range | 0.4400 - 0.4800 |
| 52 Week Range | 0.4730 - 4.500 |
| Volume | 610,804 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 576,121 |
Chart
About Silo Pharma, Inc. - Common Stock (SILO)
Silo Pharma Inc is a biotechnology company focused on leveraging psychedelic compounds and their therapeutic potential to treat various mental health conditions and neurological disorders. By researching and developing innovative drug delivery methods and formulations, the company aims to create effective treatments that can address unmet medical needs in the psychiatric space. Silo Pharma emphasizes collaboration with academic institutions and industry partners to advance its clinical programs and contribute to the evolving landscape of mental health therapies. Read More
News & Press Releases
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
Silo Pharma (NASDAQ: SILO) announced a service agreement with Resyca BV to conduct a drug-device study on the microchip-enabled nasal spray system used in its lead PTSD treatment candidate, SPC-15. The study is intended to provide the final device data needed for an Investigational New Drug (IND) application to the FDA later this year. CEO Eric Weisblum noted the device’s ability to bypass the blood-brain barrier, potentially allowing faster and safer therapeutic delivery. Silo is also progressing two other SPC-15 studies, including a GLP-compliant toxicology study and a 7-day large animal safety trial requested by the FDA.
Via Investor Brand Network · May 21, 2025
Study is expected to deliver final device data and documentation needed for planned FDA IND submission
By Silo Pharma, Inc. · Via GlobeNewswire · May 21, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
Silo Pharma (NASDAQ: SILO) a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed a public offering totaling approximately $2 million in gross proceeds. The offering included 3,333,338 shares of common stock or pre-funded warrants, along with Series A-1 and Series A-2 warrants, each allowing the purchase of up to 3,333,338 shares at $0.60 per share. The Series A-1 Warrants expire in five years, while the Series A-2 Warrants expire in eighteen months. H.C. Wainwright & Co. acted as the exclusive placement agent. Proceeds will be used for general working capital.
Via Investor Brand Network · May 19, 2025
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. The Series A-2 Warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter.
By Silo Pharma, Inc. · Via GlobeNewswire · May 16, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. The Series A-1 and A-2 warrants are immediately exercisable at $0.60 per share, with expirations set at five years and eighteen months, respectively. Gross proceeds are expected to total roughly $2 million before fees and expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent, and proceeds will support general working capital.
Via Investor Brand Network · May 16, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via Chartmill · May 15, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · May 15, 2025
InvestorkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial.
Via Investor Brand Network · May 15, 2025
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant. The Series A-1 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire five years thereafter. The Series A-2 Warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire eighteen months thereafter. The closing of the offering is expected to occur on or about May 16, 2025, subject to the satisfaction of customary closing conditions.
By Silo Pharma, Inc. · Via GlobeNewswire · May 15, 2025
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Via Stocktwits · May 14, 2025
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
By Silo Pharma, Inc. · Via GlobeNewswire · May 14, 2025
Via Benzinga · May 14, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, following a request from the FDA. The intranasal treatment targets PTSD and stress-related disorders, and the study is expected to strengthen Silo’s upcoming IND application. Silo remains on track for an FDA submission this year and is concurrently running a GLP-compliant toxicology study. SPC-15, developed in collaboration with Columbia University, is a 5-HT4 receptor agonist potentially eligible for the FDA’s 505(b)(2) pathway.
Via Investor Brand Network · May 14, 2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market
By Silo Pharma, Inc. · Via GlobeNewswire · May 14, 2025
Via Benzinga · May 1, 2025
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fibromyalgia. Conducted in minipigs, the study met all endpoints, including safety, tolerability, and pharmacokinetics, with no implant-related adverse events and sustained ketamine release for up to 22 days. CEO Eric Weisblum said the results support SP-26’s advancement as a next-generation, abuse-deterrent pain therapy. Designed for subcutaneous delivery, SP-26 avoids the dissociative effects of IV ketamine and may offer a safer alternative to opioids, potentially becoming the first at-home injectable ketamine-based therapeutic.
Via Investor Brand Network · April 30, 2025
— Successfully demonstrates strong tolerability, sustained drug release and safety
By Silo Pharma, Inc. · Via GlobeNewswire · April 30, 2025
Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.
Via Benzinga · April 30, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound exclusively licensed from Columbia University targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease. The patent covers SPC-14’s mechanism of action focused on glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies demonstrating potential improvements in cognitive memory function. The filing supports Silo’s broader intellectual property strategy for protecting its drug platforms.
Via Investor Brand Network · April 28, 2025
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University.
By Silo Pharma, Inc. · Via GlobeNewswire · April 28, 2025
Via Benzinga · March 26, 2025
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval and reduce development costs. SPC-15, a serotonin 5-HT4 receptor agonist developed in partnership with Columbia University, is intended to treat stress-related psychiatric disorders such as PTSD and anxiety.
Via Investor Brand Network · March 26, 2025